Skip to main content
Funded Studies

Ming-Kuei Jang, PhD

CEO at APRINOIA Therapeutics, Inc.

Location: Taipei, Taiwan

Dr. Ming-Kuei Jang is a cofounder and CEO of APRINOIA. He obtained his PhD in pharmacology and neuroscience from Boston University School of Medicine. He then completed two postdoctoral trainings at Northwestern University and Columbia University in neurophysiology before starting his career in pharmaceutical industry. Dr. Jang worked for Merck & Co. in Boston and West Point, Penn., as a senior research biologist for Merck’s neuroscience drug discovery laboratories, managing Alzheimer’s disease drug and biomarker discovery programs and academic and industrial collaborations. He then moved to GlaxoSmithKline in Shanghai, as an associate director in GSK’s Neurodegeneration Discovery Performance Unit where he was responsible for formulating and executing therapeutic strategies for Alzheimer’s disease. Before returning to Taiwan to found APRINOIA, Dr. Jang spent two years in MD Anderson Cancer Center in Houston, leading a newly established Alzheimer’s drug discovery consortium in collaboration with researchers from MIT, Baylor and MD Anderson.


Associated Grants

  • Alpha-Synuclein PET Imaging Tracer Development

    2019


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.